Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure–Lowering Medications

REFERENCES

• Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, AASK Collaborative Research Group. (2010). Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363:918–929.
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. (2007). Predictors of all-cause mortality in clinical ambulatory monitoring. Unique aspects of blood pressure during sleep. Hypertension 49:1235–1241.
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group. (2003). Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073–2082.
   PubMed Web of Science ®Google Scholar
• Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA. (2007). Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370:1219–1229.
   PubMed Web of Science ®Google Scholar
• Bouhanick B, Bongard V, Amar J, Bousquel S, Chamontin B. (2008). Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 34:560–567.
   PubMed Web of Science ®Google Scholar
• Brotman DJ, Davidson MB, Boumitri M, Vidt DG. (2008). Impaired diurnal blood pressure variation and all-cause mortality. Am. J. Hypertens. 21:92–97.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. (2008). Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51:1403–1419.
   PubMed Web of Science ®Google Scholar
• Crespo C, Aboy M, Fernández JR, Mojón A. (2012). Automatic identification of activity-rest periods based on actigraphy. Med. Biol. Eng. Comput. 50:329–340.
   PubMed Web of Science ®Google Scholar
• Crespo C, Fernández JR, Aboy M, Mojón A. (2013). Clinical application of a novel automatic algorithm for actigraphy-based activity and rest period identification to accurately determine awake and asleep ambulatory blood pressure parameters and cardiovascular risk. Chronobiol. Int. 30 :43–54.
   Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F, ACCORD Study Group. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. (2001). High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J. Hypertens. 19:2063–2070.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope LM, Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. (2009). Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 53:466–472.
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. (2005). Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46:156–161.
   PubMed Web of Science ®Google Scholar
• Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51:55–61.
   PubMed Web of Science ®Google Scholar
• Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegard K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA. (2010). Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J. Hypertens. 28:2036–2045.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Frauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. (2005). Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752.
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. (2003). 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21:1011–1053.
   PubMed Web of Science ®Google Scholar
• Hermida RC. (1999). Time-qualified reference values for 24 h ambulatory blood pressure monitoring. Blood Press. Monit. 4:137–147.
   PubMedGoogle Scholar
• Hermida RC. (2007). Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol. Int. 24:749–775.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2003). Sampling requirements for ambulatory blood pressure monitoring in the diagnosis of hypertension in pregnancy. Hypertension 42:619–624.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2009). Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 54:40–46.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Fernández JR. (1996). Computation of time-specified tolerance intervals for ambulatorily monitored blood pressure. Biomed. Instrum. Technol. 30:257–266.
   PubMedGoogle Scholar
• Hermida RC, Smolensky MH. (2004). Chronotherapy of hypertension. Curr. Opin. Nephrol. Hypertens. 13:501–505.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Mojón A, Fernández JR, Ayala DE. (1996). Computer-based medical system for the computation of blood pressure excess in the diagnosis of hypertension. Biomed. Instrum. Technol. 30:267–283.
   PubMedGoogle Scholar
• Hermida RC, Fernández JR, Mojón A, Ayala DE. (2000). Reproducibility of the hyperbaric index as a measure of blood pressure excess. Hypertension 35:118–125.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Fernández JR, Ruilope LM, López JE. (2002a). Evaluation of the extent and duration of the “ABPM effect” in hypertensive patients. J. Am. Coll. Cardiol. 40:710–717.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Mojón A, Fernández JR, Alonso I, Ayala DE. (2002b). The tolerance-hyperbaric test: a chronobiologic approach for improved diagnosis of hypertension. Chronobiol. Int. 19:1183–1211.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, López JE, Fernández JR, Mojón A, Domínguez MJ, Covelo M. (2003). Seasonal variation of fibrinogen in dipper and nondipper hypertensive patients. Circulation 108:1101–1106.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Fontao MJ, López JE. (2004). Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol. Int. 21:277–296.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C. (2005). Administration time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr. Opin. Nephrol. Hypertens. 14:453–459.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. (2007a). Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv. Drug Deliv. Rev. 59:923–939.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007b). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715–722.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. Fernandez JR, Mojón A, Calvo C. (2007c). Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev. Esp. Cardiol. 60:131–138.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2008). Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:69–76.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61–79.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010a). Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am. J. Hypertens. 23:432–439.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010b). Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol. Int. 27:1629–1651.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. (2011a). Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am. J. Hypertens. 24:383–391.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011b). Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 58:1165–1173.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011c). Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34:1270–1276.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011d). Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 22:2313–2321.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012a). Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am. J. Hypertens. 25:325–334.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012b). Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am. J. Hypertens. 25:297–305.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Mojón A. (2013a). Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol. Int. 30 :68–86.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. (2013b). Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol. Int. 30 :280–314.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2013c). Ambulatory blood pressure monitoring: importance of sampling rate and duration—48 versus 24 hours—on the accurate assessment of cardiovascular risk. Chronobiol. Int. 30 :55–67.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013d). Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol. Int. 30 :315–327.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013e). Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level—the “normotensive non-dipper” paradox. Chronobiol Int. 30 :87–98.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013f). Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol. Int. 30 :328–339.
   Web of Science ®Google Scholar
• Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. (2006). Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 295:2859–2866.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 45:240–245.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, for the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). (2009). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:604–612.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L. (2007). Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am. J. Kidney Dis. 50:908–917.
   PubMed Web of Science ®Google Scholar
• Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. (1998). Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal events in NIDDM subjects. Diabetes 47:1501–1506.
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. (2002). Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20:2183–2189.
   PubMed Web of Science ®Google Scholar
• Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. (2005). Effects of blood pressure levels on case fatality after acute stroke. J. Hypertens. 23:1217–1223.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH. (2010). Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol. Int. 27:1652–1667.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. (2012). Circadian rhythms and cardiovascular health. Sleep Med. Rev. 16:151–166.
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. (2008). Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168:2340–2346.
   PubMed Web of Science ®Google Scholar
• Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. (2003). Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J. Hypertens. 21:1291–1298.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. (2010). Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press. Monit. 15:173–180.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Siegel RA, Haus E, Hermida R, Portaluppi F. (2012). Biological rhythms, drug delivery, and chronotherapeutics. In Siepmann J, Siegel RA, Rathbone MJ (Eds.). Fundamentals and applications of controlled release drug delivery. Heidelberg, Germany: Springer Verlag, 359–443.
   Google Scholar
• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, ÓBrien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757–764.
   PubMed Web of Science ®Google Scholar
• Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. (2001). Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32.
   PubMed Web of Science ®Google Scholar
• Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JCM, Breteler MMB. (1999). J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 34:1181–1185.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145–153.
   PubMed Web of Science ®Google Scholar